University Medical Center, Groningen, the Netherlands
Correspondence to: Jack J. Ligtenberg, MD, University Medical Center, PO Box 30001, Groningen, 9700 RB, the Netherlands; e-mail: email@example.com
We admire the endurance of Dr. Meduri et al1in completing their ARDS study (April 2007). However, during the 10 years that passed after the start of this study there have been important changes in daily ICU practice. In the control arm, with 46% catecholamine-dependent patients, no steroids were administered in the first week. With the spread of the Surviving Sepsis Campaign,2most patients in the control arm and probably several in the treatment arm would nowadays have received low-dose steroids (100 to 300 mg/24 h). We wonder how much of the beneficial results of the study are attributable to undertreatment of the control patients. Surprisingly Dr. Annane, one of the advocates of low-dose steroid treatment in septic shock, did not mention this item in the accompanying editorial.3 We can image the enthusiasm for steroids, but the study by Meduri et al1 does not justify the unconditional title of the editorial. Even Dr. Meduri advises a further study with stratification to minimize the risks of mismatching as occurred in this study.
The authors have no conflicts of interest to disclose.
Become a CHEST member and receive a FREE subscription as a benefit of membership.
Individuals can purchase this article on ScienceDirect.
Individuals can purchase a subscription to the journal.
Individuals can purchase a subscription to the journal or buy individual articles.
Learn more about membership or Purchase a Full Subscription.
Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.